ã¡ãã£ã¢èšäº
æ°åã³ããã®æ²»çã«ã€ãã«ã¡ã¯ãã³ã¯ãäœã®å¹æããªããããšã調æ»ã§ç€ºããã
ããºãææ°ããŒã¯ 331
twitterã³ã¡ã³ã 269ä»¶äž 1ïœ100件
åœããåã®ããã«äºæž¬ã§ããäºæ¡:
åæããã£ãŠãªããããªããšãèšãããã人äœã«æäžäžå¯èœãªçšéã§å¹æãã£ãŠèšãããŠããªã
æ®éããŠã€ã«ã¹ã«å¹ãç¹å¹è¬ã£ãŠç¡ãããªãã
ã€ãã«ã¡ã¯ãã³ãå¹ããã£ãŠæåã®çºè¡šèªäœãæé ã§ãåŸããè¡ããã確èªè©Šéšãå
šãŠå€±æã«çµãã£ãŠããããšãããã€ãã«ã¡ã¯ãã³ä¿¡ä»°ã¯ç§åŠçã«ã¯ç äžã®æ¥Œé£ã§ãããªãããŸãã«å®æã
ã€ãã«ã¡ã¯ãã³ä¿¡è
ã£ãŠããã³ãã«ãããã ãªãâŠ
æ®éã«èããããã¯ã¯ãã³ãã1å²ããåããªãäœå»çæ¢ãŸã£ãŠãåœã§ãåå¥ã«è¬ã6å²ãåããããããªããã ãã©ãªâŠ
æµéèããŠãã®ããªâŠ
æ®éã«èããããã¯ã¯ãã³ãã1å²ããåããªãäœå»çæ¢ãŸã£ãŠãåœã§ãåå¥ã«è¬ã6å²ãåããããããªããã ãã©ãªâŠ
æµéèããŠãã®ããªâŠ
äžåžã¡ãããã€ãã«ã¡ã¯ãã³ããããŒïŒã¿ãããªããšããã£ã¡ã
ãèšã£ãŠãŠååŒå
ã®äººãšãã«æ¯åã®ããã«ã俺ã¯å®¶æã®åãã€ã³ãããå人茞å
¥ããïŒã¯ã¯ãã³æã€æ°ã¯ç¡ãããšãèšã£ãŠãŠæé
ããæããŠãã
ããã
ã€ãã«ã¡ã¯ãã³ã¯å¹æãªãã
å®éšãããªãè©Šéšç®¡ãããªããŠã·ã£ãŒã¬ã ããã«ã
äžçã®ããŒã¿ããéããŠãæææ§ãªããã ããæå³ãªããã
å®éšãããªãè©Šéšç®¡ãããªããŠã·ã£ãŒã¬ã ããã«ã
äžçã®ããŒã¿ããéããŠãæææ§ãªããã ããæå³ãªããã
ã€ãã«ã¡ã¯ãã³ã¯å¹æãªãã
ããããã€ãŸã§ãåããªãã
ããããã€ãŸã§ãåããªãã
ã€ãã«ã¡ã¯ãã³ã¯å¹æãªããæ¶ããïŒ
Together è©Šéšãã©ãèŠãŠãããç¥ãããã§ãã
ã¯ã¯ãã³æã¡ãããã©ãåžã®äºçŽãµã€ãã¯éå§çŽåŸã«å
šãŠã®æ
ã€ãã«ã¡ã¯ãã³ã¯WHOãèªããŠãŸãã ãRTC ïŒ ãæ¥æ¬ãæ²»éšäž â¥
ïŒåèïŒ
â GigaziNE8/13
ïŒåèïŒ
â GigaziNE8/13
æé
ãã«ãªããªããšè¯ããã©ð
ãããªèšäºããã£ãã®ã«ãã
⌠ã®æ²»çã« ã¯ãäœã®å¹æããªããããšã調æ»ã§ç€ºããã
åã¯ã¯ãã³æŽŸãCOVID-19ã®æ²»çè¬ãšããŠæšå¥šããŠããæ²»çè¬ã®ã²ãšã€ãã€ãã«ã¡ã¯ãã³ã
ããããææ°ã®ç 究ã§COVID-19ã®æ²»çã«ã¯ãäœã®å¹æããªããããšã瀺ãããã
åã¯ã¯ãã³æŽŸãCOVID-19ã®æ²»çè¬ãšããŠæšå¥šããŠããæ²»çè¬ã®ã²ãšã€ãã€ãã«ã¡ã¯ãã³ã
ããããææ°ã®ç 究ã§COVID-19ã®æ²»çã«ã¯ãäœã®å¹æããªããããšã瀺ãããã
è«äžããåé倧ãé²åãããŠã
段éã ããå®çžŸãç¡ãã®ã¯ç¢ºãã
(ÂŽ-Ïã»ïœ)
段éã ããå®çžŸãç¡ãã®ã¯ç¢ºãã
(ÂŽ-Ïã»ïœ)
æ°åã³ããã®æ²»çã« ã¯ãäœã®å¹æããªããããšã調æ»ã§ç€ºããã (2021幎08æ13æ¥)
1500人èŠæš¡ã®è©Šéšã§ãã€ãã«ã¡ã¯ãã³æäžçŸ€ãšãã©ã»ã矀ã§èšåºçµæã«å·®éã¯ã¿ãããªãã£ãã
ã¯ããçŸæç¹ã§ã¯ãã©ãžã«ã§è¡ã£ãã©ã³ãã åæ¯èŒè©Šéšãšããå»åŠçã«ã¯éèŠãªè©Šéšã®çµæç¹ã«å¹æã¯ãªããšãããã®ãå ±ããããåŸã§ãã®ã§æ ¹æ ã¯ãªããšããã®ã劥åœã§ããä»ã¢ã¡ãªã«ãšã€ã®ãªã¹ã§å¥ã®èšåºè©ŠéšãããŠãŸãããããã§ã²ã£ããè¿ããªãéãã¯æ ¹æ ãªãã§æ±ºãŸãã§ã
ããã§æ±ºçããªïŒ
å人ã®ææ³ãããç§åŠçãªæ€èšŒã®æ¹ã説åŸåããã§ãããã
å¹ããªããšãããšé°è¬ãšèšããããã§ããð€
å¹æã蚌æãããŠããªãè¬å€ã
ç¹å¹è¬ãã®ããã«æšã
å»åž«ã®å§¿å¢ã¯ãšãŠããããªãã
容èªåºæ¥ãŸãã
ç¹å¹è¬ãã®ããã«æšã
å»åž«ã®å§¿å¢ã¯ãšãŠããããªãã
容èªåºæ¥ãŸãã
åèãŸã§ãã
åºå®ãã€ãŒãå€ããã»ããããã§ããã
ãã®å
çã¯ããã®ããšãä»°ã£ãŠããã®ã§ã¯ãªãã§ããããïŒ
ã¡ãªã¿ã«æ¥æ¬ã§ã¯æ¥å¹ŽååŽçãžã®ç³è«ãç®æããŠæ²»éšãéå§ãããããªç¶æ³ãªã®ã§ããã®ãããªèšãæ¹ã«ãªãã®ã ãšæãããŸãã
ã¡ãªã¿ã«æ¥æ¬ã§ã¯æ¥å¹ŽååŽçãžã®ç³è«ãç®æããŠæ²»éšãéå§ãããããªç¶æ³ãªã®ã§ããã®ãããªèšãæ¹ã«ãªãã®ã ãšæãããŸãã
èªãŸãªã奎ã¯èªãŸãªãã ãããã
ãããªå ±éã
äžã€ã®å ±éã
äœé1kgããã400ãã€ã¯ãã°ã©ã ã®ã€ãã«ã¡ã¯ãã³ã1æ¥1åã3æ¥éã«ããã£ãŠæäžããçµæãäœã®å¹æããªãã£ãããã§ã
暪倱
åã¯ã¯ãã³æŽŸã®äººã ãé°è¬è«è ãã¡ããã€ãã«ã¡ã¯ãã³ãæ¯æãåŸãŠããŸãããããã«ã€ããŠãã«ãºæ°ã¯ããç§ãå«ãçŸå Žã§ã€ãã«ã¡ã¯ãã³ãæäžããŠããèšåºå»ã¯ãååãããæ¹å€ã«ãããããŠããŸããããŒãŒãŒ
ãšã®ããšãäœæ ãäžçäžã§è¢«ã£ãŠãæš¡æ§ã
åã¯ã¯ãã³æŽŸã®äººã ãé°è¬è«è ãã¡ããã€ãã«ã¡ã¯ãã³ãæ¯æãåŸãŠããŸãããããã«ã€ããŠãã«ãºæ°ã¯ããç§ãå«ãçŸå Žã§ã€ãã«ã¡ã¯ãã³ãæäžããŠããèšåºå»ã¯ãååãããæ¹å€ã«ãããããŠããŸããããŒãŒãŒ
ãšã®ããšãäœæ ãäžçäžã§è¢«ã£ãŠãæš¡æ§ã
1500人èŠæš¡ã®æ²»éšã§ã€ãã«ã¡ã¯ãã³ãå¹æã§ãã
â
â
倱瀌ãã€ãã«ã¡ã¯ãã³ã§ãããæå¹æ§ã¯åŠå®ãããŠããããã§ããttps://medical.jiji.com/news/44985
â 人äœã«æäžããããšãäžå¯èœãªã¬ãã«ã®æ¿åºŠã®ã€ãã«ã¡ã¯ãã³ã䜿çšãããŠããŸãã â
ã©ããªãã§ãããïŒïŒ
çµå±çŽ 人ã«ã¯çåœã¯ããããªãã§ããã
è²ã ãšéšãç«ãŠã人ããã£ã±ãããŸããã
äœã§ããææããªããã察çããã®ã1çªééããªãã
çµå±çŽ 人ã«ã¯çåœã¯ããããªãã§ããã
è²ã ãšéšãç«ãŠã人ããã£ã±ãããŸããã
äœã§ããææããªããã察çããã®ã1çªééããªãã
ãã©ãžã«ð
ãªãã€ãã«ã¡ã¯ãã³ãæšãåããããã®ããé°è¬?
ã€ãã«ã¡ã¯ãã³æšãã®å»åž«ãåºæŒããçªçµãå ±ããããããã¥ãŒã¹ãèªãã æã¯ãã€ãã«ã¡ã¯ãã³ã¯æäžäž»ãâïžã£ãŠãããã®å ±ãããæ¹ã§ãæ°ã«ãªã£ãŠèª¿ã¹ããå®éã«ã¯è«æã¯æé ãçºèŠããã補é å
ãå¹æãåŠå®ããããšãå¹æãªããã倧å¢ããããå ±ããªããšèª€è§£ãç¶ãã®ã§ã¯ð
ã«ããã§ã®æ²»éšã®çµæã
ãã£ã玹ä»ããèšäºã®æ¥æ¬ã®ãã¥ãŒã¹ã§ããâ
ã€ãã«ã¡ã¯ãã³ãäºé²è¬æ²»çè¬ã§é«ãå¹æãªããŠã·ããŠããèšã£ã¡ããã¡ã ããªãåãè¿ããã€ããªãããšã«ãªãã
ã¢ãã¬ã³ãã€ãœãžã³ãšãŸãã話é¡ã«ãªã£ãè¬ãã³ãã察çã«ã¯å
šãå¹æããªããæ¡ä»¶ã§ããããšããšããã§ã¯ã€ãã·ã§ãŒã§ãã®è¬ã®å¹èœãå説ããŠãé·å°Ÿå»åž«ã¯ã©ã責任åããã€ããã§ïŒ
ã»ã»ã»æå¹æ§ã瀺ããŠããç 究ã¯äººäœã«æäžããããšãäžå¯èœãªã¬ãã«ã®æ¿åºŠã®ã€ãã«ã¡ã¯ãã³ã䜿çšãããŠããŸãããã£ãŠã®ã¯ããŠã€ã«ã¹éæ²»ããããªãææãã人éããšãã£ãŠãã
éã絡ãããéšãã§ããå¯èœæ§ããã
ã€ãã«ã¡ã¯ãã³ãæ¬åœã«å¹æããããªããããŒã¿ã§ç€ºããŠã»ããããããã«äŒŽãèš±å¯ãåã£ãŠãããããã
ãããå»è ã§ãããåŠè ã§ããã
ã€ãã«ã¡ã¯ãã³ãæ¬åœã«å¹æããããªããããŒã¿ã§ç€ºããŠã»ããããããã«äŒŽãèš±å¯ãåã£ãŠãããããã
ãããå»è ã§ãããåŠè ã§ããã
ðŠè¯ãåãããªãã®ã¯ãã€ã³ãã§ã¯äžå®ã®å¹æãäžããŠããããš
ð€ã¯ãã³ããŠã³ã³ãšäœµãæã«ãªã£ãŠããããããïŸïŸïŸ
ð€ã¯ãã³ããŠã³ã³ãšäœµãæã«ãªã£ãŠããããããïŸïŸïŸ
å¹ããªãããã§ããå¹ããã§ãã?
ãã¡ããèªãã§ã¿ãŠãã ããã
ã¡ãªã¿ã«ãã¡ããèªãã§ãã ããã
ããªãã®å¹æããªãã
ããªãã®å¹æããªãã
ããšãã
(2021/08/13)
(2021/08/13)
ãããªãã¥ãŒã¹ããã§ãèªãã ïŒã€ãã«ã¡ã¯ãã³ãæšãæ¹
åã¯ã¯ãã³æŽŸã®åãæãã€ãã«ã¡ã¯ãã³ãã¯äœã®å¹æããªãã®ãã
æ®éã«ã¯ã¯ãã³æ¥çš®ããæ¹ãããã¿ããã ãªã
ã§ãã......‵ïžâ€µïžâ€µïž
æ®éã«ã¯ã¯ãã³æ¥çš®ããæ¹ãããã¿ããã ãªã
ã§ãã......‵ïžâ€µïžâ€µïž
(ïŸÏïŸ)ïŸïŸïŸïŸ
ãã¡ãŒãŒãŒãŒãŒãã¯ððð
æ¥ç±³æŠäºãžçªå
¥ããã®ã¯æ§ã
ãªçç±ããããšèããŠãããé£æ¥ãææ¥æ°èãªã©ãç
œããåœæ°ãéæŠãæã¿ãã¢ãããŠããããã
ãããããäžéšã ã£ãã®ãããäœæ ãã€ãã«ã¡ã¯ãã³ãäžéšã§æšããç¶ããã©ãã ãåŠå®ãããŠãæ¢ãŸããééã£ãæ¹ãžåºããã®ãèŠãŠããšãããªæããã
ãããããäžéšã ã£ãã®ãããäœæ ãã€ãã«ã¡ã¯ãã³ãäžéšã§æšããç¶ããã©ãã ãåŠå®ãããŠãæ¢ãŸããééã£ãæ¹ãžåºããã®ãèŠãŠããšãããªæããã
ãŸã ç¶ç¶ããŠç 究äžã®è©±ãªã®ã«èšãåã£ãŠãã¹ãªãŒãããã®ã¯ããããªãã®ãâŠ
GIGAZINEã¯ãã®èšäºãåºããŠãã®ã«ãã€ãã«ã¡ã¯ãã³å¹ããããšããå»å¹Žã®èšäºãã¢ããããŒããªãã«æ®ããŠããã ããããã®ãžãã¢ãã§ããã
ãçŽ äººã®ãã£ãã§ãã€ã³ãã®è«æèªãã§ç¥ã£ãŠãã¯
ããã ãå¹æãªãïŒã£ãŠèšãããŠãã®ã«ãªãã§æ¿æšããã人ãããã®ãè¬ã§ãã
å¹ããªãè¬ã宣äŒããå»è
ãå±
ãã¿ããã ãã©ãæ¢ããŠã»ãããããã®è¬ãæ¬åœã«å¿
èŠãšããŠãã人ãå°ã£ãŠãã¿ããã ãã
çé¢ç®ã«åãçµãã§ãå»åž«ã誹è¬äžå·ãããŠããããã§ããããã»ã»ã»
é°è¬è«è ãåã¯ã¯ãã³æŽŸâŠæãæã
é°è¬è«è ãåã¯ã¯ãã³æŽŸâŠæãæã
ã€ãã«ã¡ã¯ãã³ã«ã€ããŠã¯
â è«æãæ€åããã
â¡å¹æã謳ã£ãèšäºã¯ãããããè€æ°ã°ã«ãŒããæ¯èŒãããäœãç¡ããŠããªã
â¢ãã¯ãã¹ã¿ãŒå€§åŠã®æ²»éšã«ãããŠãå¹æãåŠå®ãããŠãã
ãšããç¶æ³ãªã®ã§ãåé倧åŠã§ã®æ²»éšã§è¯å¥œãªææãåºããŸã§ã¯æšå¥šããæ ¹æ ãç¡ãç¶æ ã
â è«æãæ€åããã
â¡å¹æã謳ã£ãèšäºã¯ãããããè€æ°ã°ã«ãŒããæ¯èŒãããäœãç¡ããŠããªã
â¢ãã¯ãã¹ã¿ãŒå€§åŠã®æ²»éšã«ãããŠãå¹æãåŠå®ãããŠãã
ãšããç¶æ³ãªã®ã§ãåé倧åŠã§ã®æ²»éšã§è¯å¥œãªææãåºããŸã§ã¯æšå¥šããæ ¹æ ãç¡ãç¶æ ã
ã¯ãæ€åæ€åã
å¹ããšãã人ãšå¹ããªããšãã人ãããã®ã¯æ··ä¹±ããç¶æ³ã ã
ð人äœã«æäžããããšãäžå¯èœãªã¬ãã«ã®æ¿åºŠã®ã€ãã«ã¡ã¯ãã³ãåã¯ã¯ãã³æŽŸã«æã¡èŸŒãã§ãã®äžããæ¶ããŠãããããã
ã¯ã¯ãã³ã£
åã¯ã¯ãã³æŽŸã®åžæã ã£ãã€ãã«ã¡ã¯ãã³ã
å»è ã®å ç¶ã§ã¯ãªããããŒã¿ã§ç€ºããŠããã ãããã
å»è ã®å ç¶ã§ã¯ãªããããŒã¿ã§ç€ºããŠããã ãããã
1500人ã®COVID-19æ£è
ã®ãã¡ååã«ã€ãã«ã¡ã¯ãã³ãæ®ãååã«ãã©ã»ãé ãæäžããçµæãèšåºçµæã«å·®ç°ã¯ã¿ãããªãã£ãã
èŠã¯ã軜çã®äººã«æäžãããå埩ããïŒããã軜çã ãããªïŒã¬ãã«ã®è©±ã§ãããªãã£ãã£ãŠããšã§ããããã
èŠã¯ã軜çã®äººã«æäžãããå埩ããïŒããã軜çã ãããªïŒã¬ãã«ã®è©±ã§ãããªãã£ãã£ãŠããšã§ããããã
ããããšTVããã¹ã³ããåãäžããŠããã€ãã«ã¡ã¯ãã³ã¯æ€èšŒãããå¹æããªãã£ããããª
ãªãæ²»ãæ¹ãåãäžããã®ã ããã
ææ察çããã£ãšæ·±ãæãäžããŠç§»ããªãããã«ããããšã倧äºã ãã
ããã¯ããŠã³ãæããªãå人ã§ã察çã
ãªãæ²»ãæ¹ãåãäžããã®ã ããã
ææ察çããã£ãšæ·±ãæãäžããŠç§»ããªãããã«ããããšã倧äºã ãã
ããã¯ããŠã³ãæããªãå人ã§ã察çã
å·¥äœå¡ã®ä»æ¥www
ã€ãã«ã¡ã¯ãã³äœ¿çšãããŠã¯å°ãå¢åããã®å«ãããã
ã€ãã«ã¡ã¯ãã³äœ¿çšãããŠã¯å°ãå¢åããã®å«ãããã
ã³ããææçãè延ãããä»ã®æªæãç
æ°ããã®åæžãã¯ã±ã¯ãªãã®ã§ãçŸå Žã®å»è
ã¯ãæ¬åœã«ããœã¬ãå¹ããªãã©ããªè¬ã§ã䜿ãã§ããããããªã®ã«ã£ãŠè©±ã
1500人èŠæš¡ã§ãã®çµæã
å¹æãªãã®ã ãããªããšã¯æã£ãŠãããã©ãå®éã«çµæãåºããšããªããšãããâŠâŠæ®å¿µã ãã
å¹æãªãã®ã ãããªããšã¯æã£ãŠãããã©ãå®éã«çµæãåºããšããªããšãããâŠâŠæ®å¿µã ãã
>ãªããä»åã®Together Trialã«ãããã€ãã«ã¡ã¯ãã³ã«é¢ããç 究çµæã¯ãæ£åŒãªè«æãšããŠçºè¡šããããã®ã§ã¯ãªããæ»èªããããŠããŸãã
æ»èªããããªãç¡é§ãªèª¿æ»ã
æ»èªããããªãç¡é§ãªèª¿æ»ã
ãä»åã®Together Trialã«ãããã€ãã«ã¡ã¯ãã³ã«é¢ããç 究çµæã¯ãæ£åŒãªè«æãšããŠçºè¡šããããã®ã§ã¯ãªããæ»èªããããŠããŸããã
æè¿ã®å€§èŠæš¡æ²»éšã®è©±ã¯ããããæ»èªã©ãããè«æã«ããªã£ãŠããªããããèšäº
ããã§çµè«ãèªãã®ã¯ç 究è ãšããŠèª å®æ§ã«æ¬ ããŸãã
æè¿ã®å€§èŠæš¡æ²»éšã®è©±ã¯ããããæ»èªã©ãããè«æã«ããªã£ãŠããªããããèšäº
ããã§çµè«ãèªãã®ã¯ç 究è ãšããŠèª å®æ§ã«æ¬ ããŸãã
äœããšæãã°Together Trial (ç¬)ããã
ãªãã»ã©ãã
ãšããããšã¯ãã€ãã«ã¡ã¯ãã³ã¯
æŠæŒ¢èºçæ²»çã«å¹æã絶倧ã ãšããããšã ã
ããã§ç¢ºä¿¡ãåŸãŸãããã
ãããã£ãŠã¢ãã¬ã³ãéã«è¬ãããã®ã ã
ãšããããšã¯ãã€ãã«ã¡ã¯ãã³ã¯
æŠæŒ¢èºçæ²»çã«å¹æã絶倧ã ãšããããšã ã
ããã§ç¢ºä¿¡ãåŸãŸãããã
ãããã£ãŠã¢ãã¬ã³ãéã«è¬ãããã®ã ã
ã€ãã«ã¡ã¯ãã³ã¯ãã©ãã«èšŒæãããŠãã®âïžâïžÎ£(ïŸÐŽïŸïŒ)
åé倧åŠã§ããæ²»éšãå§ãŸã£ãã°ã£ãããªããâŠâïžÎ£(ïŸÐŽïŸïŒ)
ãŸãããããããâŒïžâŒïžâŒïž
åé倧åŠã§ããæ²»éšãå§ãŸã£ãã°ã£ãããªããâŠâïžÎ£(ïŸÐŽïŸïŒ)
ãŸãããããããâŒïžâŒïžâŒïž
åããµã€ãã«æ£å察ã®çµæã®èšäºãããã
è³åŠäž¡è«ã£ãŠãã€ãâŠã
è³åŠäž¡è«ã£ãŠãã€ãâŠã
çŸç¶ã§ã¯ã»ãŒåŠå®ãããŠããç¶æ
ã®ããã§ã
ãšããã§ãã¹ã¬ãããé¡ã£ãŠãã©ãã«ããå çšããç³ãäžããŠããæ»èªåŸ ã¡æ å ±ããšãããç¡ãããã§ãããå¥ã®ã¹ã¬ãããšæ··åããŠå± ãããã®ã§ãããªâŠ?
ãšããã§ãã¹ã¬ãããé¡ã£ãŠãã©ãã«ããå çšããç³ãäžããŠããæ»èªåŸ ã¡æ å ±ããšãããç¡ãããã§ãããå¥ã®ã¹ã¬ãããšæ··åããŠå± ãããã®ã§ãããªâŠ?
ããäœã§åé倧åŠç
é¢ã§èšåºã¯ãããã®ïŒ
ä»ãŸãã«æ£åŒãªèª¿æ»ãå§ãããšãããªã®ã«ã
ä»ãŸãã«æ£åŒãªèª¿æ»ãå§ãããšãããªã®ã«ã
ã¹ã¬ããã«ãã®ãããªèšäºãã€ããŠãããæ¹ãå±
ãããŸãã
æã ç§åŠã®èŒ©ã¯ããã©ã·ãŒãå¹æã念é ã«çœ®ãã€ã€ãç§åŠçæ ¹æ ãããããå ¬è¡ã«å§ããããããå ¬è¡ã®åœã«è²¬ä»»ãæãŠããããšããä»äºãããŸã
é°è¬è«ã§è£œè¬äŒç€Ÿã®å°ä»»ç 究å¡ã®è©±ãã§ããã®ã¯ãããããTVã®äžã ãã§ã
æã ç§åŠã®èŒ©ã¯ããã©ã·ãŒãå¹æã念é ã«çœ®ãã€ã€ãç§åŠçæ ¹æ ãããããå ¬è¡ã«å§ããããããå ¬è¡ã®åœã«è²¬ä»»ãæãŠããããšããä»äºãããŸã
é°è¬è«ã§è£œè¬äŒç€Ÿã®å°ä»»ç 究å¡ã®è©±ãã§ããã®ã¯ãããããTVã®äžã ãã§ã
å¹æãªãã£ãã¿ãã
ã絡ãã§ããã°ããã®çµè«ã¯åœç¶ã®ããšãæ¢åè¬ã«å¹æããããš ã®ç·æ¥æ¿èª(ææãæ²»éš)ãã§ããªãã®ã§ã
æ°åã³ããã®æ²»çã« ã¯ãäœã®å¹æããªããããšã調æ»ã§ç€ºããã
æ°åã³ããã®æ²»çã« ã¯ãäœã®å¹æããªããããšã調æ»ã§ç€ºããã
âæå³ã®ç¡ãã¯ã¯ãã³ãªããäœãèš³ããªãïŒ
âæå³ã®ç¡ãã¯ã¯ãã³ãäœã£ãŠãäœãç®çãªã®ãïŒ
ããŠãã©ãèããã¹ãã ããïŒð€
æããŠéµåã¿ã«ããŠè¯ãã®ããªïŒ
âæå³ã®ç¡ãã¯ã¯ãã³ãäœã£ãŠãäœãç®çãªã®ãïŒ
ããŠãã©ãèããã¹ãã ããïŒð€
æããŠéµåã¿ã«ããŠè¯ãã®ããªïŒ
ã€ãã«ã¡ã¯ãã³24mgã3æ¥ã®çµæã ããã§ãã
FLCCCã®ãããã³ã«ã¯18mgã5æ¥ã§ãããã
ãä»åã®Together Trialã«ãããã€ãã«ã¡ã¯ãã³ã«é¢ããç 究çµæã¯ãæ£åŒãªè«æãšããŠçºè¡šããããã®ã§ã¯ãªããæ»èªããããŠããŸãããããšã®äºã§ããããå°ãªããšãæ»èªåŸ ã¡ã§ãã
FLCCCã®ãããã³ã«ã¯18mgã5æ¥ã§ãããã
ãä»åã®Together Trialã«ãããã€ãã«ã¡ã¯ãã³ã«é¢ããç 究çµæã¯ãæ£åŒãªè«æãšããŠçºè¡šããããã®ã§ã¯ãªããæ»èªããããŠããŸãããããšã®äºã§ããããå°ãªããšãæ»èªåŸ ã¡ã§ãã
ãã«ã²ã€ããã¹ãã³ãµãŒã«ãªã£ãŠãå£äœã®ã€ãã«ã¡ã¯ãã³ã«é¢ããç 究çµæã§ããè²ããªæãç¹ããã®ãé°è¬è«ã®ç¹åŸŽã§ãããããããé°è¬è«ãã§ããããïŒ
å·¥äœå¡ã¯å€§å¿ãïŒ
--------------------
--------------------
ãããã©ãæããŸãïŒ
ãã£ã±ããå»åŠçãªäºé ã¯èªå·±ã®çµéšã«ããæ²»ççµéšãªã©ã«çµã£ãŠã話ããããæ¹ãè¯ãããšãããããé°è¬è«è ãšåãã«ãªã£ãŠããŸããŸããããã£ã±ãã¢ã«ã³ãŒã«äŸåçã«ã€ããŠã話ããããŠæ¹ãè¯ãããšæãããã
ãã£ã±ããå»åŠçãªäºé ã¯èªå·±ã®çµéšã«ããæ²»ççµéšãªã©ã«çµã£ãŠã話ããããæ¹ãè¯ãããšãããããé°è¬è«è ãšåãã«ãªã£ãŠããŸããŸããããã£ã±ãã¢ã«ã³ãŒã«äŸåçã«ã€ããŠã話ããããŠæ¹ãè¯ãããšæãããã
ã€ãã«ã¡ã¯ãã³ã®å¹æãåŠä¿¡ããŠã¯ãããªãããã§ãã
ããŒããð€ ä»ã®ã°ã«ãŒãããã£ãããšæ²»éšããã£ãŠãæäžãªã®ã«ãäœæ
ã粟床ã®äœãæ²»éšã®ç䌌äºã§åŸãããŒã¿ãåºã«ãäœã®å¹æããªãããšæãããã®ã ãããã
ç¹å¹è¬ãªã©ãªããšæãããã®å»åž«ã®æ¬å¿ããã£ã±ãããããªã
å
ã
é©çšã®ãããç¥ç¬æ²»çãã§ã®è¬å€ç¢ºä¿ã«ãæ¯éãåºãŠããã
èã«ãçžãããæ°æã¡ã¯åãããããããå¹ãããããå¹ãããšãã話ããããã³ã«è¬å€èª¿éã«æ¯éãåºãã®ã¯ã»ããšååŒããŠã»ããã
èã«ãçžãããæ°æã¡ã¯åãããããããå¹ãããããå¹ãããšãã話ããããã³ã«è¬å€èª¿éã«æ¯éãåºãã®ã¯ã»ããšååŒããŠã»ããã
åŸãããã蟺ãšã
>Together Trialã«ãããã€ãã«ã¡ã¯ãã³ã«é¢ããç 究çµæ(ã€ãã«ã¡ã¯ãã³ã¯COVIDâ19ãŠã€ã«ã¹ã«å¹æãç¡ã)ã¯ãæ£åŒãªè«æãšããŠçºè¡šããããã®ã§ã¯ãªããæ»èªããããŠããŸããã
â
â
Together Trialã§1500人ã«å¯ŸããŠåŸæ¥ã®äœ¿çšæ¹æ³ã«å¹æµããæäžæ¹æ³ã§3å/æ¥Ã3æ¥ã§ãã©ã»ããšå·®ç°ãªããšã®ããšãæ®å¿µã§ãã
ããã®äºå®ã¯ç¹°ãè¿ãæ¡æ£ããŠããããã Together Trialã»çŽ1500人ã®COVID-19æ£è
ã»åºãæäžããã»è©Šéšã®çµæãã€ãã«ã¡ã¯ãã³ã¯ãå
šãå¹æããªãããšãããã£ãã補é 販売å
ã®äŒç€Ÿã確èª
æ®å¿µã
ã€ãã«ã¡ã¯ãã³ã¯ä»ã®ãšããã³ãããŠã€ã«ã¹ã«å¹æãªãïŒ
Ivermectin is ineffective against Covid-19, according to a recent study.
Ivermectin is ineffective against Covid-19, according to a recent study.
ãŸãããã ãšæ¿èªã¯ãããããªã
ãšããããæ··åã«ã¯ãã«çºå»è æäŸã¯ãã
ãšããããæ··åã«ã¯ãã«çºå»è æäŸã¯ãã
å¹æãããã ããªããã ãã
å¹æãããã°ãããªãšæããã©ãã
å¹æãããã°ãããªãšæããã©ãã
å㞠次ãž